Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-109

Interesting timing of this publication and this NY Times article...https://www.nytimes.com/2021/02/16/health/covid-children-inflammatory-syndrome.html?action=click&module=Top%20Stories&pgtype=Homepage

I previously linked to this study (https://pediatrics.aappublications.org/content/147/2/e2020024554) - children were evaluated with MIS-C and it found the symptoms were similar to Kawasaki-disease. The common treatment was intravenous immunoglobulin and steroids, as well as Azithromycin, Anakinra, infliximab, and hydroxychloroquine. No patients were given REM-L as I understand this was prior to the expanded access use in the States was granted.

MSB needs to come out and say what there path forward is for this. There are 30 kids in US with MIS-C and 30 kids in Sweden, plus many more across the world. There are a number of treatments, but what is MSB doing to "get to the front of the cue" given it has a published journal saying its treatment works.

2 kids treated over 6 + months - if the treatment is so successful why are we sitting around?